Response to therapy according to IWG criteria
| . | . | Arm A Day 42 (56 evaluable patients) . | Arm B Day 46 (49 evaluable patients) . | P value . |
|---|---|---|---|---|
| Initial response | CR + R | 44 (78.57%) | 45 (91.84%) | .0592 |
| NR | 12 (21.43%) | 4 (8.16%) | ||
| Arm A Arm B Day 180∗ Day 180† (43 evaluable patients) (39 evaluable patients) | ||||
| Final response | CR + R | 26 (60.47%) | 23 (58.97%) | .8907 |
| Loss of response + NR | 17 (39.53%) | 16 (41.03%) | ||
| Arm A Arm B Day 180∗ Day 180† (31 evaluable patients) (36 evaluable patients) | ||||
| Persistent response | CR + R | 25 (80.65%) | 20 (55.56%) | .0292 |
| NR | 6 (19.35%) | 16 (44.44%) | ||
| . | . | Arm A Day 42 (56 evaluable patients) . | Arm B Day 46 (49 evaluable patients) . | P value . |
|---|---|---|---|---|
| Initial response | CR + R | 44 (78.57%) | 45 (91.84%) | .0592 |
| NR | 12 (21.43%) | 4 (8.16%) | ||
| Arm A Arm B Day 180∗ Day 180† (43 evaluable patients) (39 evaluable patients) | ||||
| Final response | CR + R | 26 (60.47%) | 23 (58.97%) | .8907 |
| Loss of response + NR | 17 (39.53%) | 16 (41.03%) | ||
| Arm A Arm B Day 180∗ Day 180† (31 evaluable patients) (36 evaluable patients) | ||||
| Persistent response | CR + R | 25 (80.65%) | 20 (55.56%) | .0292 |
| NR | 6 (19.35%) | 16 (44.44%) | ||